BamSEC and AlphaSense Join Forces
Learn More

Agios Pharmaceuticals Inc.

NASDAQ: AGIO    
Share price (1/7/25): $35.12    
Market cap (1/7/25): $2.003 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 48 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Purchase and Sale Agreement Dated as of May 24, 2024 by and Between Agios Pharmaceuticals, Inc., as Seller and Royalty Pharma Investments 2019 Icav, as Purchaser
12/34/56
EX-10.21
from 10-K 25 pages Sublease Agreement
12/34/56
EX-10.4
from 10-Q 5 pages Agios Pharmaceuticals, Inc. Restricted Stock Unit Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Agios Pharmaceuticals, Inc. Restricted Stock Unit Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Agios Pharmaceuticals, Inc. Stock Option Agreement
12/34/56
EX-10.1
from 10-Q 11 pages December 16, 2022 Richa Poddar 32 Anderson Street #1 Boston, Ma 02114 Re: Confidential Separation Agreement and General Release Dear Richa
12/34/56
EX-10.43
from 10-K 5 pages Consulting Agreement
12/34/56
EX-10.38
from 10-K 12 pages Employment Agreement
12/34/56
EX-10.5
from 10-Q 16 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 18 pages Agios Pharmaceuticals, Inc. Amended and Restated Severance Benefits Plan Effective October 6, 2022
12/34/56
EX-10.5
from 10-Q 13 pages General Terms and Conditions
12/34/56
EX-10.4
from 10-Q 13 pages General Terms and Conditions
12/34/56
EX-10.3
from 10-Q 10 pages Agios Pharmaceuticals, Inc. Inducement Nonstatutory Stock Option Award Agreement
12/34/56
EX-10.2
from 10-Q 15 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Consulting Agreement
12/34/56
EX-10.44
from 10-K 12 pages Sublease Agreement
12/34/56
EX-10.2
from 10-Q 13 pages Sublease Agreement
12/34/56
EX-10.1
from 10-Q 1 page July 27, 2021 Subject: Role Change
12/34/56
EX-10.1
from 8-K 10 pages Share Repurchase Agreement
12/34/56
EX-10.2
from 10-Q 39 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Royalty Purchase Agreement by and Between Agios Pharmaceuticals, Inc. and Rpi 2019 Intermediate Finance Trust Dated as of June 11, 2020
12/34/56